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Background: Patients infected with influenza A (H1N1)pdm09 virus requiring admission to the ICU remain an
important source of mortality during the influenza season. The objective of the study was to assess the impact of a
delay in diagnosis of community-acquired influenza A (H1N1)pdm09 virus infection on clinical outcome in critically
ill patients admitted to the ICU.
Methods: A prospective multicenter observational cohort study was based on data from the GETGAG/SEMICYUC
registry (2009–2015) collected by 148 Spanish ICUs. All patients admitted to the ICU in which diagnosis of influenza
A (H1N1)pdm09 virus infection had been established within the first week of hospitalization were included. Patients
were classified into two groups according to the time at which the diagnosis was made: early (within the first 2
days of hospital admission) and late (between the 3rd and 7th day of hospital admission). Factors associated with a
delay in diagnosis were assessed by logistic regression analysis.
Results: In 2059 ICU patients diagnosed with influenza A (H1N1)pdm09 virus infection within the first 7 days of
hospitalization, the diagnosis was established early in 1314 (63.8 %) patients and late in the remaining 745 (36.2 %).
Independent variables related to a late diagnosis were: age (odds ratio (OR) = 1.02, 95 % confidence interval (CI) 1.01–1.
03, P < 0.001); first seasonal period (2009–2012) (OR = 2.08, 95 % CI 1.64–2.63, P < 0.001); days of hospital stay before ICU
admission (OR = 1.26, 95 % CI 1.17–1.35, P < 0.001); mechanical ventilation (OR = 1.58, 95 % CI 1.17–2.13, P = 0.002); and
continuous venovenous hemofiltration (OR = 1.54, 95 % CI 1.08–2.18, P = 0.016). The intra-ICU mortality was significantly
higher among patients with late diagnosis as compared with early diagnosis (26.9 % vs 17.1 %, P < 0.001). Diagnostic
delay was one independent risk factor for mortality (OR = 1.36, 95 % CI 1.03–1.81, P < 0.001).
Conclusions: Late diagnosis of community-acquired influenza A (H1N1)pdm09 virus infection is associated with a
delay in ICU admission, greater possibilities of respiratory and renal failure, and higher mortality rate. Delay in diagnosis
of flu is an independent variable related to death.
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Since the 2009 H1N1 influenza pandemic, patients with
influenza A (H1N1)pdm09 admitted to the ICU remain
an important source of mortality during the influenza
season [1, 2]. The importance of early diagnosis and
prompt start of antimicrobial treatment has been shown
consistently in critically ill patients with severe bacterial
infection or severe sepsis [3–6]. In patients with influ-
enza A, in most cases typically during epidemic periods,
antiviral treatment is administered when diagnosis is
suspected (within the first 48 hours of hospital admis-
sion), although diagnosis and treatment (between the
3rd and 7th day of admission) can be delayed because of
the lack of clinical suspicion by the medical team or
negative results in the first samples analyzed (false nega-
tives) [7, 8].
Different studies have identified factors independently
associated with mortality in patients diagnosed with influ-
enza A (H1N1)pdm09 infection [9, 10] or in selected sub-
groups, such as patients older than 65 years of age [11],
obesity [12], immunodeficiency viral infection (HIV) [13],
chronic liver disease [14], childhood [15] and pregnancy
[16], as well as in different presenting forms of infection
(severe sepsis, septic shock, pneumonia) and ICU admis-
sion [17, 18]. Also, other subsets of patients have been in-
dependently analyzed according to the presence of some
factors, such as previous influenza vaccination [19], earli-
ness of treatment with oseltamivir [20], use of corticoids
[21] or macrolides [22], or the need for invasive or nonin-
vasive mechanical ventilation on ICU admission or during
the ICU stay [23]. However, the clinical impact of a delay
in the diagnosis of influenza A (H1N1)pdm09virus infec-
tion is unknown, particularly in those patients ultimately
requiring admission to the ICU.
The objective of the study was to analyze data available in
a multicenter database of patients admitted to the ICU
diagnosed with influenza A (H1N1)pdm09 virus infection,
to determine clinical factors related to a delay in diagnosis
and the impact on the outcome of patients. It was hypothe-
sized that a delay in diagnosing influenza A (H1N1)pdm09
infection is associated with a worse clinical course and that
early identification of influenza-infected patients can
contribute to optimization of treatment.
Methods
Design and study population
This was a prospective, multicenter, observational cohort
study. Between January 1, 2009 and December 31, 2015,
data for all patients with microbiologically-confirmed
diagnosis of influenza A (H1N1)pdm09 virus infection
admitted to 148 ICUs throughout Spain were included
in the GETGAG/SEMICYUC registry (Spanish Working
Group on Severe Pandemic Influenza A (GETGAG) of
the Spanish Society of Critical Care Medicine andCoronary Units (SEMICYUC)). All patients with influ-
enza symptoms admitted to the participating ICUs were
tested for influenza A or B, and investigators voluntarily
registered all influenza A (H1N1)pdm09-positive pa-
tients in the national registry. The identification of pa-
tients was anonymized and individual patient informed
consent was not obtained given the noninterventional
nature of the study. The GETGAG/SEMICYUC registry
was approved by the Institutional Review Board of Hos-
pital Joan XXIII University Hospital of Tarragona, Spain.
All patients admitted to the ICU with clinical manifes-
tations of respiratory infection in which influenza A
(H1N1)pdm09 virus was identified during the first week
of hospital stay were included in the study. The presence
of influenza A (H1N1)pdm09 virus was confirmed by real-
time polymerase chain reaction (rt-PCR) performed ac-
cording to recommendations of the Centers for Disease
Control and Prevention (CDC) [24]. Clinical manifesta-
tions included two or more of the following signs and
symptoms: fever (>38 °C), cough, bronchial expectoration,
and myalgias associated with clinical signs of organ or sys-
tem failure (respiratory failure, hemodynamic instability,
renal failure, or altered consciousness). Exclusion criteria
were patients younger than 15 years of age, patients diag-
nosed with influenza A (H3N2) or influenza B, and pa-
tients in whom diagnosis of influenza A (H1N1)pdm09
virus infection had been established from 7 days of hos-
pital admission.
Definitions
Patients included in the study were classified into two
groups according to the time at which the diagnosis of
influenza A infection was made: early (within the first 2
days of hospital admission) and late (between the 3rd and
7th day of hospital admission). Definition of community-
acquired pneumonia was based on recommendations of
the American Thoracic Society/Infectious Diseases Society
of America (ATS/IDSA) [25].
Case report form
A case report form (CRF) was designed for data collec-
tion, including demographics (age, sex), time-related var-
iables (time between hospital admission and diagnosis of
influenza A, length of hospital stay before ICU admis-
sion, length of ICU stay, total length of hospital stay),
comorbidities, previous influenza vaccination, epidemics
season (2009–2012, 2013–2015), severity of illness, pre-
senting manifestations of infection (pneumonia, severe
asthma, acute exacerbation episode of a chronic pul-
monary disease, heart failure), treatments administered
(antivirals, inotropic drugs, corticoids, mechanical ventila-
tion, extrarenal depuration procedures), and intra-ICU
mortality. The severity of infection was assessed according
to the Acute Physiology and Chronic Health Evaluation
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Assessment (SOFA) score [27] on ICU admission. Infor-
mation was provided by physicians of the participating
ICUs according to the patient’s medical history, laboratory
data, and radiological findings. The predicted mortality
(based on APACHE II score) in the early and late diagno-
sis groups versus the observed mortality was calculated
using the online APACHE II calculator (http://clincalc.
com/IcuMortality/APACHEII.aspx).
Statistical analysis
Categorical variables are expressed as frequencies and per-
centages, and continuous variables as mean and standard
deviation (SD) when data followed a normal distribution
or as median and interquartile range (25th–75th percent-
ile) when the distribution departed from normality. Differ-
ences between groups were analyzed with the chi-square
(χ2) test or the Fisher’s exact test for categorical variables,
and the Student’s t test or the Mann-Whitney U test for
continuous variables. Significant variables in the bivariate
analysis were included in a multivariate logistic regression
model to assess independent factors associated with late
diagnosis and mortality. Odds ratios (ORs) and 95 % con-
fidence intervals (CIs) were calculated. Cumulative sur-
vival for patients with influenza A (H1N1)pdm09 virus
infection according to time of diagnosis was assessed
using the Kaplan–Meier plot. Statistical significance was
set at P < 0.05. Data were analyzed using the Statistical
Package for the Social Sciences (SPSS, Chicago, IL, USA)
for Windows 15.0.
Results
A total of 2421 patients diagnosed with influenza A
(H1N1)pdm09 virus infection were included in the GET-
GAG/SEMICYUC registry. The diagnosis was estab-
lished within the first week of hospital admission in
2059 (85.0 %) patients, 1314 (63.8 %) of whom were
classified into the early diagnosis group and 745 (36.2 %)
into the late diagnosis group (Fig. 1). Patients in the late
diagnostic group, compared with those in the early diag-
nosis group, were significantly older, showed higher sever-
ity of illness, higher percentages of immunosuppression,
hematological diseases, and chronic renal failure, required
longer hospital and ICU stay, required invasive and nonin-
vasive mechanical ventilation more frequently, required
use of vasoactive drugs, corticoids, and extrarenal depura-
tion procedures, and treatment with oseltamivir was
prescribed more lately (Table 1).
In the logistic regression analysis, independent variables
related to a delay in diagnosis of influenza A (H1N1)pdm09
virus infection were as follows: age (OR = 1.02, 95 % CI
1.01–1.03, P < 0.001); first seasonal epidemics (2009–2012)
(OR = 2.08, 95 % CI 1.64–2.63, P < 0.001); stay of in-patient
care before ICU admission (OR = 1.26, 95 % CI 1.17–1.35,P < 0.001); and need for mechanical ventilation (OR = 1.58,
95 % CI 1.17–2.13, P = 0.002) and continuous venovenous
hemofiltration (OR = 1.54, 95 % CI 1.08–2.18, P = 0.016)
(Table 1). Patients admitted to the ICU within the
first 48 hours of hospitalization showed a mean (SD)
APACHE II score of 15 (7) vs 18 (8) for patients ad-
mitted after the first 48 hours (P < 0.001). Also the
mortality rate was significantly different between ICU
admission within 48 hours of hospitalization and after
48 hours (19.4 % vs 35.2 %, P < 0.001).
The intra-ICU mortality was 17.1 % in the early diag-
nosis group (predicted 22 %) and 26.9 % in the late diag-
nosis group (predicted 23.5 %) (P < 0.001). Time to event
analysis showed an association between timing of influ-
enza A (H1N1)pdm09 diagnosis and mortality (Fig. 2),
although in both groups mortality was related to the se-
verity level (APACHE II score) on ICU admission (Fig. 3).
Independent of the severity level on admission, mortality
was significantly higher in the late diagnostic group
for APACHE II scores of 0–10 and 21–30. Statistical
significance was almost reached for APACHE II score
of 11–20 (P = 0.062) and was not significant for
scores > 30 (Fig. 3). A further subanalysis regarding
delay in oseltamivir therapy in relation to the date on
which influenza A infection was diagnosed showed no sig-
nificant differences in mortality (≤1 day vs > 1 day, 17.9 %
vs 22.8 %, P = 0.153; ≤ 2 days vs > 2 days, 19.0 % vs
23.3 %, P = 0.085; ≤ 3 days vs > 3 days, 20.6 % vs 23.2 %,
P = 0.222). In relation to immunosuppression, the mortal-
ity rate was higher in the group of late diagnosis of influ-
enza A (H1N1)pdm09 virus infection than in the early
diagnosis group both in the presence of immunosuppres-
sion (55.2 % vs 40.6 %, P = 0.046) and in the absence of
immunosuppression (22.7 % vs 14.9 %, P = 0.001).
As shown in Table 2, independent factors significantly
associated with intra-ICU mortality in patients diag-
nosed with influenza A (H1N1)pdm09 virus infection
within the first week of hospital admission included the
following: late diagnosis (OR = 1.36, 95 % CI 1.03–1.81,
P < 0.001); APACHE II score on ICU admission (OR =
1.09, 95 % CI 1.07–1.11, P < 0.001); hematological disease
(OR = 1.98, 95 % CI 1.23–3.19, P < 0.001); need for
mechanical ventilation (OR = 4.84, 95 % CI 2.73–8.56,
P < 0.001); and use of continuous venovenous hemofil-
tration (OR = 4.81, 95 % CI 3.31–7.01, P < 0.001).
Discussion
This study shows that diagnostic delay of community-
acquired influenza A (H1N1)pdm09 virus infection in
critically ill patients admitted to the ICU is a risk fac-
tor for mortality. Late versus early diagnosis of influ-
enza was associated with more days of hospitalization
before ICU admission, greater need for respiratory
support and extrarenal depuration techniques, as well
Fig. 1 Distribution of patients with influenza A (H1N1)pdm09 virus infection admitted to the ICU according to the date of diagnosis
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hospital.
The selection of 7 days as a time limit for considering
the community setting as the source of influenza A
(H1N1)pdm09 virus infection is based on the limit
established for the incubation period of the virus [28].
The incubation period estimated for the healthy popula-
tion ranges between 2 and 4 days [29, 30], although in
adult patients and in immunosuppressed patients a more
prolonged period has been described [31]. The present
study therefore considered that the origin of infection was
the community for all patients with compatible symptoms
of respiratory tract infection in whom a definitive diagno-
sis of influenza A (H1N1)pdm09 was made within the first
week of hospital admission, whereas the origin was prob-
ably nosocomial when diagnosis was established from the
second week of hospital admission.
Although the study was not designed to assess causes
of delay in diagnosis of influenza A (H1N1)pdm09 virus
infection (specific reasons were not included in the
registry), it is likely that late diagnosis may be related to
the lack of clinical suspicion of viral infection or to
negative results in the respiratory samples initially ana-
lyzed. The first case usually corresponds to patients with
suspicion of bacterial infections treated empirically with
antimicrobials with poor clinical response, and the sec-
ond case to difficulties in obtaining and/or processing
adequate samples. In the first publications of patients
admitted to the ICU with influenza A (H1N1)pdm09 virus
infection during the 2009 H1N1 influenza pandemic,
upper respiratory samples were negative in up to 20 % of
cases, so the definitive diagnosis could have been estab-
lished in samples recovered from the lower respiratory
tract [7, 8]. Obtaining new samples from bronchial aspi-
rates is thus recommended for patients with suspectedsevere viral pneumonia and negative oropharyngeal sam-
ples, and bronchoalveolar lavage samples should be col-
lected only if results of bronchial aspirates are persistently
negative [32].
In our country, we found a decrease in the number of
patients with late diagnosis during the second influenza
epidemic season, which may be due to a training effect
in the management of patients with clinical suspicion of
influenza A (H1N1)pdm09 virus infection especially dur-
ing outbreaks and due to greater availability of tech-
niques for rapid diagnosis.
In the present study, clinical characteristics associated
with diagnostic delay of influenza A (N1H1)pdm09 were
examined. Although clinically relevant differences be-
tween patients in the early and late diagnosis groups
were found for a number of variables in the univariate
analysis, only age, seasonal period, mechanical ventila-
tion, continuous venovenous hemofiltration, and days
until ICU admission were predictors of diagnostic delay
in the logistic regression analysis. In our study there was
a quite long interval between the day of blood sampling
and the onset of treatment with oseltamivir even in the
early diagnostic group, which may indicate that in most
cases treatment was not started until the physician in
charge was aware of positivity of influenza A (H1N1)pdm09
testing. Other reasons for late diagnosis, such as low degree
of vigilance or false negative tests, were not recorded. Also,
it has been shown that patients admitted to the ICU within
the first 48 hours of hospitalization had a significantly lower
severity level and mortality than those admitted to the ICU
after 48 hours of hospitalization. According to these
findings, a high level of clinical suspicion of influenza A
(H1N1)pdm09 infection in patients at risk during flu out-
breaks is needed, to establish the diagnosis as soon as pos-
sible and to reduce both delayed admission to the ICU and
Table 1 Descriptive characteristics of patients admitted to the ICU with early or late diagnosis of influenza A (H1N1)pdm09 virus
infection and independent factors related to diagnostic delay
Variable Early diagnosis
(≤2 days)
Late diagnosis
(3–7 days)
P value Odds ratio (95 %
confidence interval)
P value
Total patients 1314 745
Age (years), mean (SD) 48.43 (15.6) 51.23 (15.0) 0.001 1.02 (1.01–1.03) 0.001
Sex
Men 744 (56.6) 458 (61.4) 0.032
Women 570 (43.4) 287 (38.5)
Seasonal period
2009–2012 732 (59.45 499 (40.5) 0.001 2.08 (1.64–2.63) 0.001
2013–2015 582 (70.3) 246 (29.7)
Influenza vaccine 60 (4.6) 44 (5.9) 0.169
Comorbid conditions
Asthma 148 (11.3) 72 (9.7) 0.262
Chronic obstructive pulmonary disease 235 (17.9) 159 (21.4) 0.054
Heart failure 122 (9.3) 84 (11.3) 0.146
Chronic renal failure 81 (6.2) 69 (9.2) 0.013
Hematological disease 66 (5.0) 64 (8.6) 0.001
Obesity 459 (34.9) 269 (36.1) 0.574
Diabetes mellitus 189 (14.4) 116 (15.6) 0.432
Human immunodeficiency virus infection 32 (2.4) 15 (2.0) 0.540
Neuromuscular disease 39 (3.0) 16 (2.2) 0.269
Autoimmune disease 41 (3.1) 28 (3.8) 0.381
Immunosuppression 105 (8.0) 102 (13.7) 0.001
Pregnancy 53 (4.0) 29 (3.9) 0.879
APACHE II score, mean (SD) 15 (7) 16 (8) 0.001
SOFA score, mean (SD) 6 (3) 6 (4) 0.001
Presenting clinical manifestations
Primary viral pneumonia 1129 (85.9) 603 (81.0) 0.004
Coinfection (bacterial pneumonia) 219 (16.7) 133 (17.9) 0.458
Noninvasive mechanical ventilation 482 (36.67 314 (42.2) 0.022
Mechanical ventilation 864 (65.0) 569 (76.4) 0.001 1.58 (1.17–2.13) 0.002
Days on mechanical ventilation, median (IQR) 8 (2–15) 9 (4–20) 0.001
Vasoactive drugs 639 (48.6) 425 (57.0) 0.001
Decubitus prono 233 (17.7) 143 (19.52 0.382
Continuous venovenous hemofiltration 103 (7.8) 95 (12.8) 0.001 1.54 (1.08–2.18) 0.016
Corticoids 527 (40.1) 335 (45.0) 0.043
Days on corticoids, median (IQR) 7 (4–10) 7 (5–12) 0.071
Days until ICU admission, median (IQR) 1 (1–1) 1 (1–3) 0.001 1.26 (1.17–1.35) 0.001
Length of ICU stay (days), median (IQR) 8 (4–17) 10 (5–20) 0.001
Length of hospital stay (days), median (IQR) 14 (8–25) 18 (10–30) 0.001
Days until oseltamivir therapy, median (IQR) 4 (2–6) 5 (3–7) 0.001
Mortality rate 225 (17.1) 200 (26.9) 0.001
Data expressed as frequencies (percentages) unless otherwise stated
APACHE Acute Physiology and Chronic Health Evaluation, IQR interquartile range (25th–75th percentile), SD standard deviation, SOFA Sepsis-related Organ
Failure Assessment
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Fig. 2 Kaplan–Meier survival curves for critically ill patients admitted to the ICU with confirmed influenza A (H1N1)pdm09 in the early and late
diagnostic groups
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nonvaccinated patients (which in our study have been most
of the patients in both groups) and patients in whom vac-
cination is recommended.
The overall intra-ICU mortality was significantly
higher in the late diagnosis group. The predicted mortal-
ity based on APACHE II score on ICU admission was
higher (22 %) than the observed mortality (17.1 %) in
the early diagnosis group, but lower in the late diagnosis
group (23.5 % vs 26.9 %). The reason why delay inFig. 3 Relationship between severity of illness on ICU admission (APACHE
(H1N1)pdm09 virus infection. APACHE Acute Physiology and Chronic Healthdiagnosis of influenza A (H1N1)pdm09 virus infection is
associated with worse outcome is unclear, and a number
of factors including a difference in days until oseltamivir
therapy, delay in ICU admission, high severity of illness,
some comorbidities, or other unidentified variables
could have played a complementary role. Patients in the
late diagnosis group showed higher APACHE II and
SOFA scores on ICU admission, but data for severity of
illness on hospital admission were not recorded, so it is
unknown whether patients were already more severe onII score) and mortality in the early and late diagnosis of influenza A
Evaluation
Table 2 Patients diagnosed with influenza A (H1N1)pdm09 virus: differences between survivors and patients who died, and
independent factors related to mortality
Variable Survivors Patients who died P value Odds ratio (95 % confidence interval) P value
Total patients 1528 395
Age (years), mean (SD) 48.32 (15.24) 53.08 (15.51) 0.001
Sex
Men 865 (56.6) 255 (64.6) 0.004
Women 662 (43.4) 140 (35.4)
Seasonal period
2009–2012 941 (80.7) 225 (19.3) 0.053
2013–2015 587 (77.5) 170 (22.5)
Influenza vaccine 65 (4.3) 26 (6.6) 0.137
Comorbid conditions
Asthma 113 (11.6) 18 (6.6) 0.019
Chronic obstructive pulmonary disease 291 (19.0) 73 (18.5) 0.824
Heart failure 140 (9.2)) 53 (13.4) 0.011
Chronic renal failure 82 (5.4) 53 (13.4) 0.001
Hematological disease 65 (4.3) 52 (13.2) 0.001 1.98 (1.23–3.19) 0.001
Obesity 523 (34.2) 139 (35.2) 0.683
Diabetes mellitus 212 (13.9) 65 (16.5) 0.183
Human immunodeficiency virus infection 26 (1.7) 17 (4.3) 0.002
Neuromuscular disease 44 (2.9) 11 (2.8) 0.929
Autoimmune disease 45 (2.9) 20 (5.1) 0.036
Immunosuppression 99 (6.5) 89 (22.5) 0.001
Pregnancy 64(4.2) 11 (2.8) 0.203
APACHE II score, mean (SD) 14 (6) 21 (8) 0.001 1.09 (1.07–1.11) 0.001
SOFA score, mean (SD) 5 (3) 8 (4) 0.001
Presenting clinical manifestations
Primary viral pneumonia 1273 (83.3) 342 (86.6) 0.105
Coinfection (bacterial pneumonia) 229 (15.0) 96 (24.3) 0.001
Noninvasive mechanical ventilation 527 (34.75 141 (35.7) 0.330
Mechanical ventilation 812 (53.1) 366 (92.7) 0.001 4.84 (2.73–8.56) 0.001
Vasoactive drugs 664 (43.5) 307 (77.7) 0.001
Decubitus prono 206 (13.05 133 (33.7) 0.001
Continuous venovenous hemofiltration 67 (4.4) 116 (29.4) 0.001 4.81 (3.31–7.01) 0.001
Corticoids 500 (32.7) 196 (49.6) 0,001
Days until ICU admission, median (IQR) 1 (1–2) 1 (1–3) 0.001 1.05 (0.99–1.11) 0.117
Length of ICU stay (days), median (IQR) 8 (4–18) 9 (4–18) 0.660
Length of hospital stay (days), median (IQR) 16 (10–30) 11 (5–21) 0.001
Days until oseltamivir therapy, median (IQR) 4 (2–6) 5 (3–6) 0.054
Time of diagnosis
Early (≤2 days) 1035 (67.7) 214 (54.2) 0.001 1.36 (1.03–1.81) 0.001
Late (3–7 days) 493 (32.3) 181 (45.8)
Data expressed as frequencies (percentages) unless otherwise stated
APACHE Acute Physiology and Chronic Health Evaluation, IQR interquartile range (25th–75th percentile), SD standard deviation, SOFA Sepsis-related Organ
Failure Assessment
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due to lack of an early diagnosis, appropriate treatment,
or prompt ICU admission. Up to the present time, a
number of factors related with mortality in patients diag-
nosed with influenza A (H1N1)pdm09 virus infection
have been reported, including age, severity of illness on
admission, underlying immunosuppression, delay in
starting specific antiviral treatment (oseltamivir), dur-
ation of symptoms before the initiation of treatment,
presence of hematological or cardiac disease, need for
mechanical ventilation or extrarenal depuration tech-
niques, and dyspnea or signs of alteration of the central
nervous system on admission, among others. The present
study provides the first observation that a delay in the
diagnosis of influenza A (H1N1)pdm09 may be an inde-
pendent factor associated with a higher mortality rate.
Our data are complementary to other observations in
which mortality is related with a delay in starting
antiviral treatment and a greater duration of clinical
signs of infection prior to diagnosis of infection by
influenza A (H1N1)pdm09 virus [20]. For this reason,
in critically ill patients admitted to the ICU and be-
cause of the increase in mortality associated with a
delay in diagnosis, it is recommended to initiate anti-
viral treatment on diagnostic suspicion [32, 33].
Some limitations of the study should be taken into ac-
count. Firstly, the classification used for defining early and
late diagnosis is based on epidemiological and microbio-
logical considerations (viral shedding time) upon which
there is no consensus in the literature. The selection of 48
hours was arbitrary. Considering that the criterion to de-
fine the time of diagnosis of influenza A was the day of
blood sampling that allowed the identification of infection,
and because this technique is not available in the emer-
gency laboratories of some Spanish hospitals, 48 hours
was assumed as the cutoff point given that in many cen-
ters a sample for PCR assay was electively collected on the
next day of admission to the emergency department.
However, a further analysis with early diagnosis at ≤24
hours and late diagnosis at 2–7 days showed similar re-
sults (data not shown). Differences in clinical characteris-
tics and outcome between patients in the early and late
diagnostic groups emphasize the need for including
this classification to homogenize risk groups in future
studies. On the other hand, retrospective analysis of
an epidemiological prospective database prevents the
inclusion of new variables that might have been of
help to define the proposed classification. The multi-
center design of the study in which a therapeutic
protocol has not been established previously may be
associated with treatment bias, given that treatments
considered most adequate were those used by each
participating group. Moreover, certain variability in
the interpretation of clinical signs might be present,although consensuated definitions were used for most
study variables.
Conclusions
This study shows important differences in patients diag-
nosed with influenza A (H1N1)pdm09 virus infection
depending on the speed with which the infection is diag-
nosed. Late diagnosis of community-acquired influenza
A (H1N1)pdm09 infection is associated with a higher se-
verity of illness, delay in ICU admission, need for thera-
peutic resources, greater duration of ICU and hospital
stay, and, more importantly, higher intra-ICU mortality.
The present findings highlight the need during the epi-
demiological seasons for an early diagnosis of influenza
A (H1N1)pdm09 and prompt antiviral treatment in all
hospitalized patients with signs of respiratory infection,
independently of other clinical diagnoses.
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